Table 2.
Bivariate analysis results
| Variables | Wald | OR | Confidence interval |
|---|---|---|---|
| Age at diagnosis | 0.462 | 1.007 | 0.986–1.029 |
| Sex, women | 0.295 | 0.663 | 0.150–2.923 |
| Time of evolution of SSp | 2.291 | 0.136 | 0.99–1.085 |
| Index | |||
| ESSPRI | 0.061 | 1.015 | 0.902–1.143 |
| ESSDAI | 0.014 | 0.997 | 0.950–1.047 |
| Systemic manifestations | |||
| Inflammatory articular involvement | 5.423 | 2.075 | 1.123–3.837 |
| Pulmonar involvement | 0.018 | 0.940 | 0.378–2.338 |
| Renal involvement | 0.161 | 0.829 | 0.331–2.075 |
| Central nervous system involvement | 0.063 | 0.881 | 0.327–2.375 |
| Glandular inflammation | 0.298 | 0.852 | 0.479–1.578 |
| Peripheral nervous system involvement | 0.009 | 1.048 | 0.392–2.798 |
| Digestive involvement | 1.524 | 0.635 | 0.308–1.306 |
| Hematologic involvement | 0.300 | 1.166 | 0.673–2.021 |
| Pathological labial salivary gland biopsy | 5.835 | 0.501 | 0.286–0.878 |
| Analysis | |||
| ANA + | 0.374 | 0.526 | 0.067–4.121 |
| RF + | 0.900 | 0.736 | 0.391–1.386 |
| AntiRo + | 2.116 | 0.224 | 0.030–1.681 |
| AntiLa + | 0.527 | 0.800 | 0.438–1.461 |
Factors associated with severe dry eye in SSp